Since 2006, one-year treatment (17 cycles) with trastuzumab in combination with chemotherapy has been offered as standard treatment in Denmark to women with early-stage HER2-positive breast cancer before or after surgery. This evidence concerns the gene ERBB2 and breast cancer.